This report explores the case of a young, normal-responder nulligravida with peritoneal endometriosis and recurrent implantation failure, with poor embryo quality during multiple failed attempts at IVF treatment. The patient …
Background: Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic …
Background: Cerebral endometriosis is an exceptionally rare manifestation of extrapelvic endometriosis and remains a diagnostic challenge because its clinical and imaging features may mimic more common neurological, inflammatory, vascular, or …
To evaluate the effectiveness and tolerability of dienogest in patients with endometriosis in real-world clinical practice.
To compare the clinical effectiveness of combined oral contraceptive pills (levonorgestrel-containing COC) and dienogest in the management of endometriosis-associated chronic pelvic pain and related symptoms.
Dienogest Evidence Comes With Real-World Tradeoffs streamlinefeed.co.ke
A 27-year-old nulliparous woman presented with chronic pelvic pain (CPP) (8/10 on the Numerical Rating Scale (NRS)), dysmenorrhea, heavy menstrual bleeding (HMB), and a family history of endometriosis. She had …
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Corsicana Daily Sun
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Voice of Alexandria
The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …